Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Volume just changed
I see that purchase on TD.
That happens sometimes. Doesn’t mean halted.
I bought 45 shares at $5.25. They went through but not shown on Level 2.
I don't see that.
Where do you see that?
There are $14M reasons from those billionaires why RXMD will skyrocket very very soon.
This will go violent once right news drop. It will come, very soon.
Thank you. That really helps clear up the situation.
$RXMD
"Power Hour" let's make it happen, Captain.
Thing is cash in the bank has been increasing, well over 8 million now.
Yes agree these are longterm holders.
Yeah the dilution from these additional investments isn’t great, but these shares held by Fernandez and company should all be long. Far different from CV/Iliad converting on open market
So if the price goes up just a dollar, Jay’s stock value goes up $127K. Not sure what argument you’re trying to make. Their percentage of overall holdings compared to pre-split is still largely the same. Reserve splits do not change the company market cap.
I hope it does well for us. I'm shoveling my lunch down then back to business.
Keep rolling rolling rolling.
Time will tell. I'm still underwater bigly. I hope this continues to correct north.
Good luck.
I took out the 4.35 and part of the 4.50
I got orders at 4.09 and 4.10 this morning. Wish I bought cheaper. Oh well
Record quarterly revenue of $11.4M is just a starter. NextPlat and other individual healthcare entrepreneurs have invested over $14M in RXMD. Huge plans are brewing right now. Boom time is coming if some major news drop.
I'm tracking an OS of a little over 5M. Still an extremely low OS with around half of it being restricted. This one is way undervalued in my opinion.
https://www.otcmarkets.com/stock/RXMD/security
Don't know how official this source is, but according to it Mr Ferdandez owns shares followingly:
I got curious about ownership as your list does not include NXPL, Fernandez, or Barreto. So I went to the SEC filings and looked at ownership. Those three entities do own common shares.
The latest SC 13 D/A dated 5/4/23 lists info on this but there has to be an error in the amount reported for NextPlat. Per the entries and notes they own 90% of the common stock. Not likely. So I looked at applying the RS 1:200. That is also unreasonable. I'm stuck.
$RXMD
LOL!! whatever you say. Have you seen the 10-Q.
Look at the volume. This thing is a dead POS. What a waste.
I will let someone else break it down, but they do have a lot of stock which will be in OS, but agree they do have stock to convert which will not be in that.
Shares acquired by NXPLs Fernandez & Baretto were preferred shares. I see what mean you about them having skin in the game, however - those warrants and preferred series shares are different than the common shares within the float and OS that retail investors are able to trade.
I will agree with one thing, we do need an update as to plans going forward, problem is when that update comes you will probably be left behind if you don’t hold shares.
It’s clear from recent Q results, that business is going pretty well. With continued profit margin increases, PBM fees hopefully being reduced due to legislation and debt interest gone, we will show a good profit in this Q.
NXPL have the right to purchase enough shares in RXMD to take their holding above 50%, there is no need to keep share price down any longer.
The BID/ASK spread of .32 cents (Citadel on both sides of the trade) is an clear indication on how low the demand for RXMD shares has become. Makes RXMD ripe for day trading and manipulation under these circumstances.
With the continued silent treatment from CEO and lack of any significant milestones to be heard of, this will keep trading sideways until further hints of a plan are communicated to shareholders.
I am looking at now, not in the past.
Due to the holdings of NXPL and our CEO and Vice Chairman there are a lot of shares that are held tight, float is low.
Only 3 insiders currently hold a position in RXMD over the past 2 years.
Cecil Munnik - 532k
Birute Norkute - 8.1m
Jay Weisberg - 25.3m
These are the numbers reported in October 2022, prior to that sneaky RS Fernandez pulled on the last trading day of December 2022. Jay stood to gain the most, until his 25m holding was reduced to 126k now.
After RS is applied to these holdings a whopping 170k shares of the OS are held by insiders, an minimal percentage of the current OS of slightly over 3M
That's even better. Activity picking up here.
And how many shares are held insiders that will not sell, can’t leave a lot, reason we will see large swings up and down.
I mean we have $7 to $8 million in the bank, market cap of around 20 million and will 100% show a good profit in this Q with revenue probably trending towards 45 to 50 million this year, if not more with potential deals.
I also agree. With an OS of a little over 3 million, it won't take much to kick the share price higher.
I agree number of available shares is low, any news which increases volume is going to spike share price north. It really would not take much for this to go to $10 and above in a flash.
That's not really true anymore. Rs changed that. You can't buy in big numbers without the price shooting up.
Aint that the truth. Its been a long wait, need more than a wash.
Me too, but I'm not looking to break even.
Gentlemen there's enough riches for everyone, no need to argue.
Yes Turbo, on the surface it looks like a nice pop into closing, however upon looking at that trades printed, it was the two 100 share block "paint job" trade(s) that occured 10 minutes before closing bell, thus resulting in the 6% gain seen today.
BUYS: 1,041
SELLS: 727
Overall it was mostly a flat day of trading, a total of only 13 executed trades today, which is well below where this needs to be to see any significant movement. Of course the currently muted CEO hasn't helped the situation neither.
Again, nice close. Still a ways for me to break even.
This one is huge. Phillip Frost is a highly recognized and successful entrepreneur in Healthcare industry for the past 60 years. His personal investment of $6M in NextPlat’s healthcare sector and RXMD is a clear signal where the company is going. The first thing you see on the front page of NextPlat website is “Digitalizing Healthcare”. Over $14M have been moved into RXMD by NextPlat, including the investment from Phillip Frost. What’s about to come will be a game changer plan for both companies.
Taken from the sec filing in the Q.
The Company raised $6.0 million through a private offering of its common stock priced above the market. The new growth capital will support the expansion of its offerings into the rapidly growing healthcare sector through its previous strategic investment in Progressive Care Inc., a provider of personalized healthcare services and technology, and support additional business development programs, partnerships, and marketing activities.
No references in the Frost filings on April 14th about RXMD, I believe what you are referring to is the PowerPoint presentation created by NXPL last month. SEC filings are what matter most, not a slideshow created by an NXPL graphic artist within their Marketing Dept.
Followers
|
731
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
196263
|
Created
|
01/09/11
|
Type
|
Free
|
Moderators gedi8 Truth022809 stockforce TrackDude |
Progressive Care Gains SEC Reporting Status
See on website
Miami, FL – April 12, 2022 – Globe Newswire via NewMediaWire – Progressive Care, Inc. (OTCQB: RXMD) (the “Company”), a personalized healthcare services and technology provider, today announced that, effective April 11, 2022, its Registration Statement on Form 10 filed with the U.S. Securities and Exchange (the “SEC”) to register its shares of common stock under Section 12(g) of the Securities Exchange Act of 1934 (the “Exchange Act”) became automatically effective.
The effective Form 10 obligates the Company to file Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, in addition to complying with all other obligations under the Exchange Act. In addition, management and certain shareholders are subject to the beneficial ownership reporting requirements of Section 13 and 16 of the Exchange Act.
Alan Jay Weisberg, Chairman and Chief Executive Officer of the Company said, “For me, it was always important to have the Company become fully reporting with the SEC. I know how critical it is for individual and institutional investors to have the Company file its financial reports with the SEC as it provides a higher level of confidence in the information reported by the Company and a superior level of transparency. I believe that the Company’s compliance with the Exchange Act will ultimately help drive shareholder value and enable us to access higher quality institutional capital. We remain committed to strong corporate governance and steadfast in pursuit of our journey to Nasdaq.”
To view the Form 10 filling, please click:
https://www.sec.gov/Archives/edgar/data/0001402945/000149315222009357/form10-12ga.htm
Key Financial Highlights for Year Ended December 31, 2021
• Revenue at $38.9 million
- COVID-19 testing revenue of approximately $4.3 million
- ClearMetrX TPA and pharmacy dispensing revenue related to 340B earned $2.8 million on total billings of $19 million
• Gross margin increased to 26% in 2021, from 23% in 2020
• EBITDA increased to $167,000 in 2021 from $7,000 in 2020
• Cash balance of $1.4 million as of December 31, 2021
Business Highlights for the Year Ended December 31, 2021
• Re-implemented upgraded pharmacy software system
• Expanded COVID-19 business into corporate-focused services and institutional clients
• Strengthened reputation in the 340B sector by adding eight new contracts
• Filed initial S-1 registration statement
• Submitted application for uplisting to Nasdaq
Q4 2021 Reflected a Positive Bounce Back in Business
• Increase of 10% in prescription revenue to $8.9 million in the fourth quarter of 2021, from $8.1 million in the third quarter of 2021
• Increase of 8% in prescriptions filled to 114,000 in the fourth quarter of 2021, from 106,000 in the third quarter of 2021
PRODUCTS AND SERVICES
Advances in HIV/AIDS treatment has greatly increased the ability of those suffering from the disease to manage their symptoms and live longer, healthier lives. Effective management of the disease begins with taking the right medications with the right dose at the right times. For those in the HIV/AIDS community, adhering to the very strict dietary and medicinal requirements can be extremely difficult. Normal activities are often interrupted and sometimes prevented by the struggle to be in compliance.
PharmCo wants to ease this burden on those impacted by this life altering disease. We aim to make compliance with prescription regiments as easy as possible. By understanding the sensitive nature of HIV/AIDS and the needs of those afflicted, PharmCo provides the following services to patients with these special needs:
1. Confidential packaging
2. Packaging tailored to suit a patient's individual life style
3. Free delivery from a variety of sources including PharmCo's proprietary delivery fleet
4. A staff that is well trained in acute illnesses, who understands the patient's needs and
concerns
5. 24 hour emergency support
6. Timely availability of specialty medications due to our extensive inventory
7. Access to newly developed medications
PharmCo is a fully accredited DME supplier. In November 2010, as part of Medicare's competitive bidding, PharmCo was awarded a three year contract to supply hospital beds, oxygen supplies, power wheelchairs, scooters, walkers, and other related equipment and accessories in South Florida. PharmCo carries an extensive inventory of equipment and accessories with most special requests being honored with same day or next day delivery. The company offers both sales and rentals with size, color, style, and brand options available on the majority of products. Most importantly, the staff is knowledgeable, helpful and dedicated to providing superior customer service.
PharmCo offers home service and maintenance, defective product replacements, and free home installation and instruction.
PharmCo's institutional clients have come to depend on the company's proven accuracy, dispensing methods, and immediate response time. With PharmCo compliance and efficiency assistance, long term care institutions are able to provide the highest level of continued care to their patients. PharmCo provides purchasing, repackaging and dispensing of both prescription and non-prescription pharmaceutical products. PharmCo utilizes a unit-of-dose packaging system as opposed to traditional vials used for its retail customers. This method of distribution improves control and patient compliance with recommended drug therapy by increasing the timeliness and accuracy of medication dispensing. PharmCo also provides computerized maintenance of patient prescription histories, third party billing and consultant pharmacist services. Its consulting services consist primarily of evaluation of monthly patient drug therapy and monitoring the institution’s drug distribution system.
Long term care institutions can count on PharmCo for the following services:
1. On time, same day deliveries available twice a day with 24 hour emergency support
2. Language assistance in English, Spanish, French, Creole, Portuguese, Russian, and Hebrew
3. Unit-dose packaging options tailored the facility's needs
4. Prescription data accuracy
5. Extensive medication and DME inventory
6. Access to OTC medications, nutritional products and personal hygiene items
7. Provision and review of medication carts
8. Monthly pharmacy consultations- drug interactions, redundant therapies, side effects, etc.
9. Compliance updates and consultations
10. Staff Training
11. Exceptional customer service.
Toll Free: 888-919-7411 Phone: 305-919-7399 Fax: 305-919-7424
HOURS
Monday- Thursday 8:30 AM - 6:30 PM
Friday 8:30 AM - 6:00 PM
Saturday 11:00 AM - 4:00 PM
PharmCo currently services: Miami-Dade, Broward, Palm Beach, Martin, and St. Lucie Counties.
Progressive Care Reports Full Year 2021 Financial Results Highlighted by $38.9 Million in RevenueGLOBENEWSWIRE – 11:16 AM ET 03/29/2022 |
Progressive Care’s PharmcoRx Gains Status as Approved COVID-19 Test Vendor in the U.S. for Travel to Beijing Winter Olympic Games in ChinaGLOBENEWSWIRE – 7:00 AM ET 02/02/2022
|
Posts Today
|
0
|
Posts (Total)
|
196263
|
Posters
|
|
Moderators
|
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |